Below is our recent interview with Jason Wallace from Emerald Cloud Lab:
Q: Jason, what is Emerald Cloud Lab?
A: Emerald Cloud Lab (ECL) is a technology company that provides researchers with access to state-of-the-art scientific labs from anywhere on Earth 24 hours a day, 365 days a year using a single computer interface.
Q: Any highlights on your recent announcement?
A: ECL has established a new AI Scientific Advisory Board composed of expert researchers from various scientific disciplines to help provide guidance and establish ethical frameworks, policies, and procedures for the use of large language models such as ChatGPT4 in scientific research.
Q: Can you give us more insights into your offering?
A: ECL has created a new digital workflow where researchers utilize a single computer interface to design, run and analyze experiments in cloud lab environments which allow researchers to spend more time developing novel approaches to experiment design and analyzing results, and less time on manual, time-intensive tasks in the lab.
Q: What can we expect from your company in the next 6 months? What are your plans?
A: In the next six months, ECL will launch a massive state-of-the-art cloud laboratory centrally located in Austin, Texas. A facility equipped with over 230 types of instruments designed to help accelerate innovative research in the life science industries. We will also help bring a second state-of-the-art cloud lab online at Carnegie Mellon University in Pittsburgh. Both new facilities will be part of a newly established network of cloud labs designed to serve the scientific community.
Q: What is the best thing about your company that people might not know about?
A: One of the best things about ECL the public may not be aware of is that we are a mission-driven organization dedicated to democratizing scientific research by providing convenient and affordable access to the most advanced lab facilities and equipment worldwide, enabling researchers to pursue groundbreaking discoveries and drive innovation. To this end, we currently support the research of large pharmaceutical and biotech companies as well as start-ups and academic institutions.